• Yuqian Wu, Kai Wang, Jingyang Su, and Xin Liu.
• Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
• Medicine (Baltimore). 2024 Feb 23; 103 (8): e36916e36916.

ObjectTo evaluate the efficacy and safety of dorzagliatin for the treatment of type 2 diabetes (T2DM).MethodsSeven databases were systematically searched, spanning the interval from 2016 to August 2023. Randomized controlled trials (RCTS) comparing dorzagliatin with placebo for the treatment of T2DM were applicable for containing this study. The relevant data were extracted, and a meta-analysis was implemented using RevMan 5.4 software.ResultsA total of 3 studies involving 1332 patients were included. We use glycated hemoglobin (HbA1c) levels as the major indicator of efficacy, FBG, 2h postprandial blood glucose, Homa-β and Homa-IR to be Secondary outcome measures. Compared with placebo group, dorzagliatin significantly reduced blood glucose levels as well as enhanced insulin resistance. In terms of safety, no serious adverse events occurred. However, lipid-related indicators, especially triglycerides levels, and the incidence of hypoglycemia were higher in patients in the dorzagliatin group compared with those in the control group, but the increase from baseline was mild.ConclusionsDorzagliatin exerted favorable effects in hypoglycemic control, effectively reduced the HbA1c, FBG, and 2h postprandial blood glucose levels in T2DM patients, stimulated the secretion of insulin during the initial phase, and exerted a consistent hypoglycemic effect. However, the incidence of adverse events such as elevated blood lipids and cardiovascular risk warrants further investigations through long-term clinical trials.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

29 keywords...

hide…